Cargando…
Low antileishmanial drug exposure in HIV-positive visceral leishmaniasis patients on antiretrovirals: an Ethiopian cohort study
BACKGROUND: Despite high HIV co-infection prevalence in Ethiopian visceral leishmaniasis (VL) patients, the adequacy of antileishmanial drug exposure in this population and effect of HIV-VL co-morbidity on pharmacokinetics of antileishmanial and antiretroviral (ARV) drugs is still unknown. METHODS:...
Autores principales: | Kip, Anke E, Blesson, Séverine, Alves, Fabiana, Wasunna, Monique, Kimutai, Robert, Menza, Peninah, Mengesha, Bewketu, Beijnen, Jos H, Hailu, Asrat, Diro, Ermias, Dorlo, Thomas P C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050768/ https://www.ncbi.nlm.nih.gov/pubmed/33677546 http://dx.doi.org/10.1093/jac/dkab013 |
Ejemplares similares
-
Impact of the Use of a Rapid Diagnostic Test for Visceral Leishmaniasis on Clinical Practice in Ethiopia: A Retrospective Study
por: Diro, Ermias, et al.
Publicado: (2015) -
A randomized trial of AmBisome monotherapy and AmBisome and miltefosine combination to treat visceral leishmaniasis in HIV co-infected patients in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019) -
Host transcriptomic signature as alternative test-of-cure in visceral leishmaniasis patients co-infected with HIV
por: Adriaensen, Wim, et al.
Publicado: (2020) -
Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia
por: Diro, Ermias, et al.
Publicado: (2019) -
Characterizing the non-linear pharmacokinetics of miltefosine in paediatric visceral leishmaniasis patients from Eastern Africa
por: Palić, Semra, et al.
Publicado: (2020)